Biohaven Licenses IgG Degrader Portfolio to Ono Pharmaceutical
Biohaven Pharmaceuticals (BHVN) has entered into a licensing agreement with Japan's Ono Pharmaceutical, granting them rights to develop and commercialize Biohaven’s MoDE pan IgG degrader portfolio in several Asian countries. The technology is designed to degrade disease-causing proteins outside cells, potentially offering new therapeutic options for various conditions. This partnership expands Biohaven's global reach by leveraging Ono's expertise in the Asia-Pacific region. Financial terms of the deal were not disclosed, but such licensing agreements often include upfront payments and milestone-based royalties or sales shares. The move aligns with industry trends toward out-licensing innovative drug platforms to maximize development potential. The agreement could provide Biohaven with a steady revenue stream from future milestones and commercial success in Asia while allowing Ono to expand its pipeline of novel therapeutics.
Topics: drug development international expansion pharma partnership